Therapeutic Drug Monitoring MarketSize and Trends

Personalized medicine and advanced technologies such as assay performance and drug monitoring to fuel the growth of therapeutic drug monitoring market

Personalized medicine is driving the growth of therapeutic drug monitoring market, owing to increasing demand for better treatment outcome with minimum side effects from the medication. For instance, TDM is majorly used for anti-cancer drugs monitoring for which standard guidelines are recommended by many oncology Journal and associations, one of them being the European Journal of Oncology. Moreover, advanced treatment therapies such pharmacogenomics, gene testing, and proteomics is further expected to boost the growth of market. Increasing antimicrobial resistance is one of the key factor driving the growth of TDM market. According to WHO Factsheet 2017, antimicrobial resistance is one of the leading cause of death. For instance, according to WHO factsheet, around 4,80,000 multi-drug resistance TB cases were reported, which is creating an opportunity for physicians to optimize or monitor the drug therapies through TDM.

Organ transplant procedures are also propelling the growth of therapeutic drug monitoring market. Immunosuppressant drugs are basic treatment for organ transplant to avoid rejection of transplanted organ by body, which requires TDM to avoid ADR and side effects. Asia Pacific is a promising region for organ transplant due to increased awareness and infrastructure availability. According to Waters Corporation Blog, China witnessed 35% y-o-y increase in organ transplant in the first 4 months of 2017. There is a growing trend of clinical research organizations being shifted to cost effective Asia Pacific region for bioequivalence study of generic drugs on account of low cost of processes in this region. Moreover, advances in the field of biomedical technology such as nano biosensors and implantable devices are expected to boost the growth of therapeutic drug monitoring market. Advancement in tools for TDM such as assay kits, chromatography columns, spectrometry, and alternative matrices such as interstitial fluid provide continuous real time monitoring of the therapeutic drug through Probe Scientific’s new MicroEye Technology.